2021 TURNOVER
EXCEPTIONAL LEVEL OF €184.1 MILLION
• Continued growth in non-COVID activities (+14%)
• Share of proprietary products increasing to 25%
• Limited decline in COVID activities (-12%) in a context of sharp price declines
• Record level of cash at more than 100 M euros
Maintaining a high level of activity
- A still very high level of sales related to COVID diagnosis (€102.6 million, or 56% of sales), despite sharply declining prices compared to the previous year;
- Continued growth in traditional activities, excluding COVID (€81.5m, i.e. 44% of sales).
en M€ | 2021 | 2020 | var. | |
COVID | 102.6 | 117.0 | -12.2% | |
Excluding COVID | 81.5 | 71.5 | +13.6% | |
Total | 184.1 | 188.5 | -2.3% | |
not audited |
A range of COVID diagnostics with high added value
Even if
The share of proprietary products increased significantly, building upon
- - A reinforced R&D capability;
- - Strong regulatory affairs;
- - A new responsive and high-capacity production tool.
Indeed, the Group was the first to obtain in
COVID revenue was thus down a limited 12% over the year, in a context of a sharp drop in prices linked to the massive arrival of products from
Strong growth in revenue excluding COVID at +14% (+10% organic)
During the second half of the year, marked by a new wave of contamination, health and diagnostic players were again strongly focused on the diagnosis and treatment of COVID, at the expense of other pathologies. Growth of the Group's non-COVID activities nevertheless remains high during the year, at +14% (+10% at constant scope, by eliminating the activity of TECOmedical in the first half of 2021) with revenues of €81.4 million.
Each of the Group's three traditional business segments (transplantation, diseases and medical research) grew. The growth of the Diseases division was the most impacted by the mobilization of the various players on COVID.
In addition to the development of new proprietary product lines,
In addition, the development of international sales continued during the year, supported by the foreign subsidiaries TECOmedical and Pathways as well as by the signing of new customers, particularly in the
More than €100 million in cash
At the end of 2021,
These significant financial resources allow the group to pursue its strategic development by investing in R&D, and in targeted external growth in order to continue to increase the share of its international sales.
The significant share of proprietary products sales should help maintain a good level of results in 2021.
Next financial meeting
2021 annual results:
Disclaimer This press release contains elements that are not historical facts including, without limitation, certain statements about future expectations and other forward-looking statements. Such statements are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, profitability or events to differ materially from those anticipated. In addition, |
Attachment
- PR_Eurobio Scientific_CA_2021_EN
![](https://ml-eu.globenewswire.com/media/MWJiMGFkNmQtYjg1Zi00YTRlLTgxNjEtMWM0YjU4ZjBhOTBiLTEwMTE1NTU=/tiny/Eurobio-Scientific.png)
© OMX, source